La voce delle donne. Il punto con Luisa Betti Dakli

Roma, 31 gennaio 2022 – Primo appuntamento del 2022 con Luisa Betti Dakli, giornalista esperta in diritti umani e direttrice del giornale online DonnexDiritti Network. La trasmissione, condotta da Luce Tommasi, si tiene ogni ultimo lunedì del mese ed è come sempre incentrata sulle tematiche dei diritti al femminile e, oltre a sviluppare temi d’attualità sulla parità di genere, entra nel merito della video inchiesta “Crimini invisibili”, che di settimana in settimana affronta i problemi connessi alla violenza sulle donne. In questa puntata si parla in particolare di “figli strappati” e “alienazione parentale”. Partecipano alla trasmissione, insieme a Luisa Betti Dakli, anche Laura Massaro,
presidente del Comitato Madri Unite contro la violenza istituzionale e Marinella De Maffutiis, responsabile dell’Ufficio Comunicazione dell’Anmil.

 

3 thoughts on “La voce delle donne. Il punto con Luisa Betti Dakli

  • [url=https://www.tcspharmaceuticals.com/pro/Liothyronine_sodium_55-06-1_t3_for_weight_loss_usage_and_formulation.html]liothyronine[/url] is a manufactured form of the thyroid hormone triiodothyronine (t3). it is most commonly used to treat hypothyroidism and myxedema coma. it is generally less preferred than levothyroxine. it can be taken by mouth or by injection into a vein.

    side effects may occur from excessive doses. this may include weight loss, fever, headache, anxiety, trouble sleeping, arrythmias, and heart failure. use in pregnancy and breastfeeding is generally safe. regular blood tests are recommended to verify the appropriateness of the dose being taken.

    liothyronine was approved for medical use in 1956. it is available as a generic medication. a month’s supply in the united kingdom costs the nhs about gb?247 as of 2019. in the united states the wholesale cost of this amount is about us$22.40. in 2017, it was the 252nd most commonly prescribed medication in the united states, with more than one million prescriptions.

    medical uses
    liothyronine is a generally less preferred option to levothyroxine (t4) for people with hypothyroidism. it may be used when there is an impaired conversion of t4 to t3 in peripheral tissues. the dose of liothyronine for hypothyroidism is a lower amount than levothyroxine due it being a higher concentrated synthetic medication. about 25 µg of liothyronine is equivalent to 100 µg of levothyroxine.

    in thyroid cancer or graves’ disease, ablation therapy with radioactive iodine (131i) can be used to remove trace thyroid tissue that may remain after thyroidectomy (surgical excision of the gland). for 131i therapy to be effective, the trace thyroid tissue must be avid to iodine, which is achieved by elevating the person’s tsh levels. for patients taking levothyroxine, tsh may be boosted by discontinuing levothyroxine for 3–6 weeks. this long period of hormone withdrawal is required because of levothyroxine’s relatively long biological half-life, and may result in symptoms of hypothyroidism in the patient. the shorter half-life of liothyronine permits a withdrawal period of two weeks, which may minimize hypothyroidism symptoms. one protocol is to discontinue levothyroxine, then prescribe liothyronine while the t4 levels are falling, and finally stop the liothyronine two weeks before the radioactive iodine treatment.

    liothyronine may also be used for myxedema coma because of its quicker onset of action when compared to levothyroxine. use for the treatment of obesity is not recommended.

Lascia un commento

Il tuo indirizzo email non sarà pubblicato.